ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Tripos reviews its options

January 16, 2006 | APPEARED IN VOLUME 84, ISSUE 3

Tripos has retained the advisory firm Seven Hills Partners to help it explore various strategic options, including mergers and acquisitions, becoming a private company, and separating its businesses in drug discovery informatics and chemistry research. Tripos' announcement comes three weeks after the company disclosed that it will cut staff in its chemistry research business now that a four-year program to make druglike molecules for Pfizer has ended. Separately, Tripos says that Wyeth will pay $5 million to license Tripos' informatics technology for use in drug discovery.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment